文献速递重症综合管理与镇静镇痛

辛伐他汀早期给药预防和治疗机械通气危重症患者谵妄的评估(MoDUS):一项随机、双盲、安慰剂对照试验

Evaluation of early administration of simvastatin in the prevention and treatment of delirium in critically ill patients undergoing mechanical ventilation (MoDUS): a randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet Respir Med · 2017-07-19
一句话结论在需机械通气的危重症成人中,每日辛伐他汀80 mg与安慰剂相比未显著延长14天内无谵妄且无昏迷的存活天数。

MoDUS是一项在Watford综合成人ICU开展的随机、双盲、安慰剂对照试验,纳入142例≥18岁、入住72小时内需机械通气的危重症患者,1:1随机接受辛伐他汀80 mg每日或安慰剂,最长28天。主要终点为随机后14天内无谵妄且无昏迷的存活天数,辛伐他汀组平均5.7天(SD 5.1)vs 安慰剂组6.1天(SD 5.2),平均差0.4天(95%CI -1.3至2.1;P=0.66),无显著差异。最常见不良事件为肌酸激酶升高至正常上限10倍以上(辛伐他汀组8例[11%] vs 安慰剂组3例[4%],P=0.208),无与研究药物相关的严重不良事件。作者认为结果不支持辛伐他汀可改变危重症患者谵妄和昏迷持续时间的假设。

要点

  • 需机械通气的危重症成人中,辛伐他汀80 mg每日与安慰剂相比,14天内无谵妄且无昏迷存活天数无显著差异(5.7天 vs 6.1天,平均差0.4天,95%CI -1.3至2.1;P=0.66)。
  • 肌酸激酶升高至正常上限10倍以上在辛伐他汀组8例(11%)vs 安慰剂组3例(4%),P=0.208,无与研究药物相关的严重不良事件。
  • 作者结论:结果不支持辛伐他汀可改变危重症患者谵妄和昏迷持续时间的假设。
  • 研究在Watford综合成人ICU开展,纳入≥18岁、入住72小时内需机械通气的患者,辛伐他汀80 mg每日最长28天。

适用人群与场景

  • 在Watford综合成人ICU纳入的危重症患者,≥18岁,入住72小时内需机械通气。

诊断标准与关键阈值

  • 谵妄评估采用ICU意识模糊评估法(CAM-ICU)。

处置流程与药物剂量

  • 随机1:1接受辛伐他汀80 mg每日或安慰剂,最长28天,不论昏迷或谵妄状态。

研究设计与关键结果

  • 随机、双盲、安慰剂对照试验,142例患者随机接受辛伐他汀(n=71)或安慰剂(n=71),均纳入最终分析。
  • 主要终点14天内无谵妄且无昏迷的存活天数:辛伐他汀组5.7天(SD 5.1)vs 安慰剂组6.1天(SD 5.2),平均差0.4天(95%CI -1.3至2.1;P=0.66),无显著差异。
  • 最常见不良事件为肌酸激酶升高至正常上限10倍以上:辛伐他汀组8例(11%)vs 安慰剂组3例(4%),P=0.208。
  • 无患者发生与研究药物相关的严重不良事件。

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照试验。
  • 作者结论:结果不支持辛伐他汀可改变危重症患者谵妄和昏迷持续时间的假设。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为结果不支持辛伐他汀可改变危重症患者谵妄和昏迷持续时间的假设。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Delirium in critically ill patients is associated with poor clinical outcomes. Neuroinflammation might be an important mechanism in the pathogenesis of delirium, and since simvastatin has anti-inflammatory properties it might reduce delirium. We aimed to establish whether early treatment with simvastatin would decrease the time that survivors of critical illness spent in delirium or coma.

METHODS: We undertook this randomised, double-blind, placebo-controlled trial in a general adult intensive care unit (ICU) in Watford General Hospital (Watford, UK). We enrolled critically ill patients (≥18 years) needing mechanical ventilation within 72 h of admission. We randomly assigned patients (1:1 ratio) to receive either simvastatin 80 mg or placebo daily for up to a maximum of 28 days, irrespective of coma or delirium status. We assessed delirium using the Confusion Assessment Method for the ICU (CAM-ICU). The primary outcome was number of days alive and was assessed as delirium-free and coma-free in the first 14 days after being randomly allocated to receive treatment or placebo. ICU clinical and research staff and patients were masked to treatment. We did intention-to-treat analyses with no extrapolation. This trial is registered with the International Standard Randomised Controlled Trial Registry, number ISRCTN89079989.

FINDINGS: Between Feb 1, 2013, and July 29, 2016, 142 patients were randomly assigned to receive simvastatin (n=71) or placebo (n=71), and were included in the final analysis. The mean number of days alive without delirium and without coma at day 14 did not differ significantly between the two groups (5·7 days [SD 5·1] with simvastatin and 6·1 days [5·2] with placebo; mean difference 0·4 days, 95% CI -1·3 to 2·1; p=0·66). The most common adverse event was an elevated creatine kinase concentration to more than ten times the upper limit of normal (eight [11%] in the simvastatin group vs three [4%] in the placebo group p=0·208). No patient had a serious adverse event related to the study drug.

INTERPRETATION: These results do not support the hypothesis that simvastatin modifies duration of delirium and coma in critically ill patients.

FUNDING: National Institute for Health Research.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Page VJ, Casarin A, Ely EW, et al. Evaluation of early administration of simvastatin in the prevention and treatment of delirium in critically ill patients undergoing mechanical ventilation (MoDUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2017. PMID: 28734823. doi:10.1016/S2213-2600(17)30234-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。